"Mazindol" from_date:2012

Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D. In this randomized double-blind study, 137 participants received 1 mg mazindol (n = 65) alone or combined with 500 mg metformin (n = 72), twice a day, for 6 months. Mazindol and mazindol-metformin were similarly effective. However, when subjects were subclassified into non-diabetics and prediabetics, according to glycated hemoglobin (HbA1c) - < 5.7% and 5.7 - 6.4%, respectively - and/or fasting plasma glucose (FPG) - < 100 mg/dL and 100 - 125 mg/dL

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) Mazindol is under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD) because of its alertness-enhancing properties. A novel controlled-release (CR) formulation of mazindol was developed to allow once-daily dosing. The aim of this study was to evaluate the efficacy of mazindol CR in adults with ADHD. We conducted a randomized, double-blind, placebo-controlled 6-week trial. Subjects diagnosed with ADHD using the Mini-International Neuropsychiatric Structured Interview (MINI) and with an ADHD Rating Scale, Diagnostic

Repeated administration of mazindol reduces spontaneous pain-related behaviors without modifying bone density and microarchitecture in a mouse model of complete Freund’s adjuvant-induced knee arthritis The role of dopaminergic system in the development of rheumatoid arthritis-related pain, a major symptom in this disease, has not been explored. Therefore, the anti-nociceptive effect of mazindol, a dopamine uptake inhibitor, was evaluated in a model of complete Freund's adjuvant (CFA)-induced arthritis. Furthermore, as studies have shown that the dopaminergic system regulates bone metabolism, the effect of mazindol on bone mass and microarchitecture was determined. Adult ICR male mice received intra-articular injections of either CFA or saline into the right knee joint every week

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness.Approximately 48 participants will take part in the study across the United States.The study treatment (NLS-2 or placebo ) will be administered for 8 weeks. After this treatment period, the participant may have the option to participate in a separate long-term extension study during which all participants will be treated with NLS-2. This is a Phase 3, double-blind, placebo-controlled, multicenter, randomized, parallel-group clinical trial. The primary goal of this study is to assess the efficacy and safety of NLS-2 (mazindol extended

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-weeks. undefined

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy This is a multicenter, open-label extension of the clinical study NLS-1021, evaluating long-term safety, tolerability, pharmacokinetics (PK), and therapeutic response to treatment with NLS-2 in adult subjects with narcolepsy. undefined

and included 19 completed RCTs (one trial is awaiting assessment). A total of 2216 participants entered the trials, 1280 participants were randomly assigned to fluoxetine (60 mg/d, 40 mg/d, 20 mg/d and 10 mg/d) and 936 participants were randomly assigned to various comparison groups (placebo; the anti-obesity agents diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine

an important role in the molecular pathology of MDD and BD. To test this hypothesis, we measured levels of [H]mazindol binding to DAT in Brodmann's area (BA) 10, BA 17 as well as in the dorsal and ventral striatum from 15 controls, 15 patients with MDD and 15 patients with BD, obtained postmortem, using in situ radioligand binding with autoradiography. Compared to controls, levels of [H]mazindol binding to DAT was significantly higher in BA10 from patients with MDD but not BD. There was no significant difference in [H]mazindol binding to DAT in BA 17 or the dorsal and ventral striatum from patients with MDD or BD. In addition, levels of [H]mazindol binding show no correlation with donor age, postmortem interval, tissue pH, sex or duration of illness. In conclusion, our data suggest that changes

to lifestyle modification and be combined with diet, physical activity and behaviour modification. (pg 65)Grade A, Level 1+C Drug therapy may be considered when BMI is ≥ 30 kg/m2, or when BMI is 27.5–29.9 kg/m2 in Asians with comorbidities or complications of obesity such as hypertension, Type 2 diabetes mellitus. (pg 65)Grade C, Level 2+A Phentermine and mazindol may be used for weight

• Mazindol • Methcathinone • Methylphenidate • Pemoline • Phendimetrazine • Phentermine • Phenylpropanolamine CNS depressants Alcohol11 Barbiturates GHB (gamma–hydroxybutrate) Some solvents/inhalants Kava Pituri Benzodiazepines12 • Diazepam • Temazepam • Alprazolam • Clonazepam • Oxazepam • Nitrazepam • Lorazepam Cannabinoids13 • Cannabis/marijuana • Butane hash oil • Medicinal

authorised and the person witnessing the destruction must be authorised to do so.Schedule 3 (controlled drugs - no register)Includes the barbiturates (except secobarbital, which is now Schedule 2), buprenorphine, gabapentin, mazindol, meprobamate, midazolam, pentazocine, phentermine, pregabalin, temazepam, and tramadol hydrochloride.Safe custody requirements do apply, except for any 5,5 disubstituted barbituric acid (eg, phenobarbital), gabapentin, mazindol, meprobamate, midazolam, pentazocine, phentermine, pregabalin, tramadol hydrochloride, or any stereoisomeric form or salts of the above.They are subject to the same special handwriting requirements as Schedule 2 CDs.There is no legal requirement to record transactions in a CD register.The requirements relating to destruction do not apply unless

and ALK2 gene mutations * * Subgroup 3 - Drug- and toxin-induced PAH (Aminorex, fenfluramine derivatives, and toxic rapeseed oil have been identified as definite risk factors for PAH. [1] Other drugs implicated as possible risk factors for PAH include amphetamine and amphetamine derivatives, cocaine, L-tryptophan, phenylpropanolamine, St. John’s wort, leflunomide, phentermine, mazindol, dasatinib